Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

Originally published as JCO Early Release 10.1200/JCO.2003.02.063 on February 7 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henderson, I. C.
Right arrow Articles by Norton, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henderson, I. C.
Right arrow Articles by Norton, L.
Journal of Clinical Oncology, Vol 21, Issue 6 (March), 2003: 976-983
© 2003 American Society for Clinical Oncology

Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

I. Craig Henderson, Donald A. Berry, George D. Demetri, Constance T. Cirrincione, Lori J. Goldstein, Silvana Martino, James N. Ingle, M. Robert Cooper, Daniel F. Hayes, Katherine H. Tkaczuk, Gini Fleming, James F. Holland, David B. Duggan, John T. Carpenter, Emil Frei, III, Richard L. Schilsky, William C. Wood, Hyman B. Muss, Larry Norton

From the University of California at San Francisco, San, Francisco, CA; Cancer and Leukemia Group B (CALGB) Statistical Center, Durham; Wake Forest University School of Medicine, Winston-Salem, NC; University of Texas M.D. Anderson Cancer, Houston; Southwest Oncology Group Operations, San, Antonio, TX; Dana-Farber Cancer Institute, Boston, MA; Eastern Cooperative Oncology Group Operations, Philadelphia, PA; North Central Cancer Treatment Group Operations, Rochester, MN; Georgetown University Medical Center, Washington, DC; University of Michigan, Ann Arbor, MI; Greenbaum Cancer Center, Baltimore, MD; University of Chicago Medical Center; and CALGB Central Office, Chicago, IL; Mount Sinai School of Medicine; and Memorial Sloan-Kettering Cancer Center, New York; State University of New York Health Science Center at Syracuse, Syracuse, NY; University of Alabama at Birmingham, Birmingham, AL; and University of Vermont, Burlington, VT.

Address reprint requests to I. Craig Henderson, MD, University of California at San Francisco, 1600 Divisadero St, Box 1710, San Francisco, CA 94143; email: craig.henderson{at}accessoncology.com.

Purpose: This study was designed to determine whether increasing the dose of doxorubicin in or adding paclitaxel to a standard adjuvant chemotherapy regimen for breast cancer patients would prolong time to recurrence and survival.

Patients and Methods: After surgical treatment, 3,121 women with operable breast cancer and involved lymph nodes were randomly assigned to receive a combination of cyclophosphamide (C), 600 mg/m2, with one of three doses of doxorubicin (A), 60, 75, or 90 mg/m2, for four cycles followed by either no further therapy or four cycles of paclitaxel at 175 mg/m2. Tamoxifen was given to 94% of patients with hormone receptor–positive tumors.

Results: There was no evidence of a doxorubicin dose effect. At 5 years, disease-free survival was 69%, 66%, and 67% for patients randomly assigned to 60, 75, and 90 mg/m2, respectively. The hazard reductions from adding paclitaxel to CA were 17% for recurrence (adjusted Wald {chi}2 P = .0023; unadjusted Wilcoxon P = .0011) and 18% for death (adjusted P = .0064; unadjusted P = .0098). At 5 years, the disease-free survival (± SE) was 65% (± 1) and 70% (± 1), and overall survival was 77% (± 1) and 80% (± 1) after CA alone or CA plus paclitaxel, respectively. The effects of adding paclitaxel were not significantly different in subsets defined by the protocol, but in an unplanned subset analysis, the hazard ratio of CA plus paclitaxel versus CA alone was 0.72 (95% confidence interval, 0.59 to 0.86) for those with estrogen receptor–negative tumors and only 0.91 (95% confidence interval, 0.78 to 1.07) for patients with estrogen receptor–positive tumors, almost all of whom received adjuvant tamoxifen. The additional toxicity from adding four cycles of paclitaxel was generally modest.

Conclusion: The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.

Supported in part by grant no. CA31946 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, to the CALGB (R.L.S.).

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.




This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
M. Martin, A. Rodriguez-Lescure, A. Ruiz, E. Alba, L. Calvo, M. Ruiz-Borrego, B. Munarriz, C. A. Rodriguez, C. Crespo, E. de Alava, et al.
Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
J Natl Cancer Inst, June 4, 2008; 100(11): 805 - 814.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Hudis and C. Dang
The Taxane Limbo: How Low Can We Go?
J Natl Cancer Inst, June 4, 2008; 100(11): 761 - 763.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G. Fountzilas, U. Dafni, H. Gogas, H. Linardou, H. P. Kalofonos, E. Briasoulis, D. Pectasides, E. Samantas, D. Bafaloukos, G. P. Stathopoulos, et al.
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
Ann. Onc., May 1, 2008; 19(5): 853 - 860.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Sparano, M. Wang, S. Martino, V. Jones, E. A. Perez, T. Saphner, A. C. Wolff, G. W. Sledge Jr., W. C. Wood, and N. E. Davidson
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
N. Engl. J. Med., April 17, 2008; 358(16): 1663 - 1671.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Puhalla, E. Mrozek, D. Young, S. Ottman, A. McVey, K. Kendra, N. J. Merriman, M. Knapp, T. Patel, M. E. Thompson, et al.
Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer
J. Clin. Oncol., April 1, 2008; 26(10): 1691 - 1697.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Dang, M. Fornier, S. Sugarman, T. Troso-Sandoval, D. Lake, G. D'Andrea, A. Seidman, N. Sklarin, M. Dickler, V. Currie, et al.
The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer
J. Clin. Oncol., March 10, 2008; 26(8): 1216 - 1222.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. A. Perez, V. J. Suman, N. E. Davidson, G. W. Sledge, P. A. Kaufman, C. A. Hudis, S. Martino, J. R. Gralow, S. R. Dakhil, J. N. Ingle, et al.
Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial
J. Clin. Oncol., March 10, 2008; 26(8): 1231 - 1238.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
L.-P. P. Tran and J. L. Grabinski
Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux
Journal of Pharmacy Practice, February 1, 2008; 21(1): 46 - 56.
[Abstract] [PDF]

Home page
 Ann OncolHome page
L. Del Mastro, B. Dozin, E. Aitini, T. Catzeddu, E. Baldini, A. Contu, A. Durando, S. Danese, G. Cavazzini, G. Canavese, et al.
Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group
Ann. Onc., February 1, 2008; 19(2): 299 - 307.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. De Laurentiis, G. Cancello, D. D'Agostino, M. Giuliano, A. Giordano, E. Montagna, R. Lauria, V. Forestieri, A. Esposito, L. Silvestro, et al.
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
J. Clin. Oncol., January 1, 2008; 26(1): 44 - 53.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. E. Cazzaniga, G. Mustacchi, P. Pronzato, A. De Matteis, F. Di Costanzo, I. Floriani, and On behalf of the NORA Study Group
Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study
Ann. Onc., December 1, 2007; 18(12): 1976 - 1980.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. F. Hayes, A. D. Thor, L. G. Dressler, D. Weaver, S. Edgerton, D. Cowan, G. Broadwater, L. J. Goldstein, S. Martino, J. N. Ingle, et al.
HER2 and Response to Paclitaxel in Node-Positive Breast Cancer
N. Engl. J. Med., October 11, 2007; 357(15): 1496 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
A. Moore
Breast-Cancer Therapy -- Looking Back to the Future
N. Engl. J. Med., October 11, 2007; 357(15): 1547 - 1549.
[Full Text] [PDF]

Home page
 JCOHome page
H. B. Muss, D. A. Berry, C. Cirrincione, D. R. Budman, I. C. Henderson, M. L. Citron, L. Norton, E. P. Winer, and C. A. Hudis
Toxicity of Older and Younger Patients Treated With Adjuvant Chemotherapy for Node-Positive Breast Cancer: The Cancer and Leukemia Group B Experience
J. Clin. Oncol., August 20, 2007; 25(24): 3699 - 3704.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Denduluri, J. A. Low, J. J. Lee, A. W. Berman, J. M. Walshe, U. Vatas, C. K. Chow, S. M. Steinberg, S. X. Yang, and S. M. Swain
Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes
J. Clin. Oncol., August 10, 2007; 25(23): 3421 - 3427.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. M. Gonzalez-Angulo, B. T. Hennessy, K. Broglio, F. Meric-Bernstam, M. Cristofanilli, S. H. Giordano, T. A. Buchholz, A. Sahin, S. E. Singletary, A. U. Buzdar, et al.
Trends for Inflammatory Breast Cancer: Is Survival Improving?
Oncologist, August 1, 2007; 12(8): 904 - 912.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Layman, D. G. Thomas, K. A. Griffith, J. B. Smerage, M. A. Helvie, M. A. Roubidoux, K. M. Diehl, L. A. Newman, M. S. Sabel, J. A. Hayman, et al.
Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4092 - 4097.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Verma and M. Clemons
First-Line Treatment Options for Patients with HER-2 Negative Metastatic Breast Cancer: The Impact of Modern Adjuvant Chemotherapy
Oncologist, July 1, 2007; 12(7): 785 - 797.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. L. Henry and D. F. Hayes
Can Biology Trump Anatomy? Do All Node-Positive Patients With Breast Cancer Need Chemotherapy?
J. Clin. Oncol., June 20, 2007; 25(18): 2501 - 2503.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sui, Y. Huang, B. H. Park, N. E. Davidson, and W. Fan
Estrogen Receptor {alpha} Mediates Breast Cancer Cell Resistance to Paclitaxel through Inhibition of Apoptotic Cell Death
Cancer Res., June 1, 2007; 67(11): 5337 - 5344.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. C.F. Moore, S. J. Green, J. R. Gralow, S. I. Bearman, D. Lew, W. E. Barlow, C. Hudis, A. C. Wolff, J. N. Ingle, H. K. Chew, et al.
Intensive Dose-Dense Compared With High-Dose Adjuvant Chemotherapy for High-Risk Operable Breast Cancer: Southwest Oncology Group/Intergroup Study 9623
J. Clin. Oncol., May 1, 2007; 25(13): 1677 - 1682.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. U. Buzdar
Adjuvant Chemotherapy for High-Risk Operable Breast Cancer
J. Clin. Oncol., May 1, 2007; 25(13): 1642 - 1644.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
The Adjuvant Breast Cancer Trials Collaborative Gr
Polychemotherapy for Early Breast Cancer: Results From the International Adjuvant Breast Cancer Chemotherapy Randomized Trial
J Natl Cancer Inst, April 4, 2007; 99(7): 506 - 515.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
N Wilking, E Lidbrink, T Wiklund, B Erikstein, H Lindman, P Malmstrom, P Kellokumpu-Lehtinen, N-O Bengtsson, G Soderlund, G Anker, et al.
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
Ann. Onc., April 1, 2007; 18(4): 694 - 700.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Buchholz, A. V. Schally, J. B. Engel, F. Hohla, E. Heinrich, F. Koester, J. L. Varga, and G. Halmos
Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel
PNAS, February 6, 2007; 104(6): 1943 - 1946.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Piedbois, D Serin, F Priou, P Laplaige, S Greget, E Angellier, E Teissier, J-F Berdah, M Fabbro, B Valenza, et al.
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study
Ann. Onc., January 1, 2007; 18(1): 52 - 57.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. T. Chlebowski, G. L. Blackburn, C. A. Thomson, D. W. Nixon, A. Shapiro, M. K. Hoy, M. T. Goodman, A. E. Giuliano, N. Karanja, P. McAndrew, et al.
Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study
J Natl Cancer Inst, December 20, 2006; 98(24): 1767 - 1776.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. Roche, P. Fumoleau, M. Spielmann, J.-L. Canon, T. Delozier, D. Serin, M. Symann, P. Kerbrat, P. Soulie, F. Eichler, et al.
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
J. Clin. Oncol., December 20, 2006; 24(36): 5664 - 5671.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Walshe, N. Denduluri, and S. M. Swain
Amenorrhea in Premenopausal Women After Adjuvant Chemotherapy for Breast Cancer
J. Clin. Oncol., December 20, 2006; 24(36): 5769 - 5779.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. E. Jones, M. A. Savin, F. A. Holmes, J. A. O'Shaughnessy, J. L. Blum, S. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. Kirby, et al.
Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer
J. Clin. Oncol., December 1, 2006; 24(34): 5381 - 5387.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. N. Levine and T. Whelan
Adjuvant Chemotherapy for Breast Cancer -- 30 Years Later
N. Engl. J. Med., November 2, 2006; 355(18): 1920 - 1922.
[Full Text] [PDF]

Home page
 JCOHome page
C. Lohrisch, C. Paltiel, K. Gelmon, C. Speers, S. Taylor, J. Barnett, and I. A. Olivotto
Impact on Survival of Time From Definitive Surgery to Initiation of Adjuvant Chemotherapy for Early-Stage Breast Cancer
J. Clin. Oncol., October 20, 2006; 24(30): 4888 - 4894.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
D. A. Berry, L. Inoue, Y. Shen, J. Venier, D. Cohen, M. Bondy, R. Theriault, and M. F. Munsell
Chapter 6: Modeling the Impact of Treatment and Screening on U.S. Breast Cancer Mortality: A Bayesian Approach
J Natl Cancer Inst Monographs, October 1, 2006; 2006(36): 30 - 36.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. B. Lamont, J. E. Herndon II, J. C. Weeks, I. C. Henderson, C. C. Earle, R. L. Schilsky, and N. A. Christakis
Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344).
J Natl Cancer Inst, September 20, 2006; 98(18): 1335 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. P. McGuire
Is it time for some new approaches for treating advanced ovarian cancer?
J Natl Cancer Inst, August 2, 2006; 98(15): 1024 - 1026.
[Full Text] [PDF]

Home page
 Ann OncolHome page
P. S. Hupperets and V. C. Tjan-Heijnen
Primary or secondary G-CSF prophylaxis to support TAC chemotherapy in breast cancer?
Ann. Onc., August 1, 2006; 17(8): 1181 - 1183.
[Full Text] [PDF]

Home page
 JCOHome page
T. J. Smith, J. Khatcheressian, G. H. Lyman, H. Ozer, J. O. Armitage, L. Balducci, C. L. Bennett, S. B. Cantor, J. Crawford, S. J. Cross, et al.
2006 Update of Recommendations for the Use of White Blood Cell Growth Factors: An Evidence-Based Clinical Practice Guideline
J. Clin. Oncol., July 1, 2006; 24(19): 3187 - 3205.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. B. Elkin, A. Hurria, N. Mitra, D. Schrag, and K. S. Panageas
Adjuvant Chemotherapy and Survival in Older Women With Hormone Receptor-Negative Breast Cancer: Assessing Outcome in a Population-Based, Observational Cohort
J. Clin. Oncol., June 20, 2006; 24(18): 2757 - 2764.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. Maruvada and S. Srivastava
Joint national cancer institute-food and drug administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection.
Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1078 - 1082.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Tanner, J. Isola, T. Wiklund, B. Erikstein, P. Kellokumpu-Lehtinen, P. Malmstrom, N. Wilking, J. Nilsson, and J. Bergh
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401
J. Clin. Oncol., June 1, 2006; 24(16): 2428 - 2436.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Bogart, S. L. Seagren, and A. Glicksman
Radiation oncology research in the cancer and leukemia group B.
Clin. Cancer Res., June 1, 2006; 12(11): 3628s - 3634s.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. K. Plevritis, A. W. Kurian, B. M. Sigal, B. L. Daniel, D. M. Ikeda, F. E. Stockdale, and A. M. Garber
Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
JAMA, May 24, 2006; 295(20): 2374 - 2384.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. O. Hanrahan, V. Valero, A. M. Gonzalez-Angulo, and G. N. Hortobagyi
Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature
J. Clin. Oncol., May 1, 2006; 24(13): 2113 - 2122.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al.
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. A. Berry, C. Cirrincione, I. C. Henderson, M. L. Citron, D. R. Budman, L. J. Goldstein, S. Martino, E. A. Perez, H. B. Muss, L. Norton, et al.
Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
JAMA, April 12, 2006; 295(14): 1658 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. Woloshin and L. M. Schwartz
What's the rush? The dissemination and adoption of preliminary research results.
J Natl Cancer Inst, March 15, 2006; 98(6): 372 - 373.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. H. Giordano, Z. Duan, Y.-F. Kuo, G. N. Hortobagyi, J. Freeman, and J. S. Goodwin
Impact of a scientific presentation on community treatment patterns for primary breast cancer.
J Natl Cancer Inst, March 15, 2006; 98(6): 382 - 388.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Chakravarthy, M. C. Kelley, B. McLaren, C. I. Truica, D. Billheimer, I. A. Mayer, A. M. Grau, D. H. Johnson, J. F. Simpson, R. D. Beauchamp, et al.
Neoadjuvant Concurrent Paclitaxel and Radiation in Stage II/III Breast Cancer
Clin. Cancer Res., March 1, 2006; 12(5): 1570 - 1576.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, F. Cardoso, C. Bernard, and M. J. Piccart
Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.
Oncologist, February 1, 2006; 11(2): 111 - 125.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
I. Smith and S. Chua
Medical treatment of early breast cancer. III: chemotherapy
BMJ, January 21, 2006; 332(7534): 161 - 162.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Llombart Cussac, et al.
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Clin. Cancer Res., December 15, 2005; 11(24): 8715 - 8721.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Venturini, L. Del Mastro, E. Aitini, E. Baldini, C. Caroti, A. Contu, F. Testore, F. Brema, P. Pronzato, G. Cavazzini, et al.
Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial
J Natl Cancer Inst, December 7, 2005; 97(23): 1724 - 1733.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
B. K Moser and S. L George
A general formulation for a one-sided group sequential design
Clinical Trials, December 1, 2005; 2(6): 519 - 528.
[Abstract] [PDF]

Home page